Steatohepatitis/Metabolic Liver Disease News

Based on the current number of cases of non-alcoholic steatohepatitis in the United States, more than $175 billion will be spent on managing and treating the disease, two-thirds being spent in those with obesity and NASH, according to a presentation.

Aldafermin did not reach statistical significance on dose-dependent improvement in fibrosis on liver biopsy in patients with nonalcoholic steatohepatitis, according to a presentation at The Liver Meeting Digital Experience.

Terns Pharmaceuticals announced positive top-line results from a phase 1 clinical trial of TERN-501, a thyroid hormone receptor beta agonist for the treatment of nonalcoholic steatohepatitis, according to a press release.

The FDA granted fast track designation to LPCN 1144 as a treatment for non-cirrhotic nonalcoholic steatohepatitis, according to a release from Lipocine.

LAS VEGAS – In this video exclusive, Nancy S. Reau, MD, FAASLD, AGAF, discussed the Liver Health Annual Trends Report, which was launched during a panel discussion hosted by Salix Pharmaceuticals at the ACG Annual Scientific Meeting.

LAS VEGAS – In this video exclusive, Donna Cryer, JD, founder, president and CEO Global Liver Institute, spoke on the launch of the Liver Health Annual Trends Report and its possible impact for patients with chronic liver disease.

Lean and non-lean patients with nonalcoholic fatty liver disease were similar metabolically and had common risk factors, according to findings published in the Journal of Gastroenterology and Hepatology Open.

Waist circumference independently correlated with the risk for advanced fibrosis among patients with type 2 diabetes, according to a presenter at the European Association for the Study of Diabetes Annual Meeting.

Fatty pancreas independently correlated with diabetes mellitus but not hypertension or dyslipidemia, according to research published in Clinical Gastroenterology and Hepatology.

Protara Therapeutics announced results of a study designed to further understand the incidence of intestinal failure-associated liver disease in patients dependent on parenteral nutrition.